The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
Aneta Mikulasova,
Christopher P. Wardell,
Alexander Murison,
Eileen M. Boyle,
Graham H. Jackson,
Jan Smetana,
Zuzana Kufova,
Ludek Pour,
Viera Sandecka,
Martina Almasi,
Pavla Vsianska,
Evzen Gregora,
Petr Kuglik,
Roman Hajek,
Faith E. Davies,
Gareth J. Morgan,
Brian A. Walker
Affiliations
Aneta Mikulasova
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA;Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic;Department of Medical Genetics, University Hospital Brno, Czech Republic;Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
Christopher P. Wardell
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Alexander Murison
Center for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK
Eileen M. Boyle
Center for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK
Graham H. Jackson
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Jan Smetana
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic;Department of Medical Genetics, University Hospital Brno, Czech Republic
Zuzana Kufova
Faculty of Medicine, University of Ostrava, Czech Republic;Department of Hematooncology, University Hospital Ostrava, Czech Republic
Ludek Pour
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic
Viera Sandecka
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic
Martina Almasi
Department of Clinical Hematology, University Hospital Brno, Czech Republic
Pavla Vsianska
Department of Clinical Hematology, University Hospital Brno, Czech Republic
Evzen Gregora
Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
Petr Kuglik
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic;Department of Medical Genetics, University Hospital Brno, Czech Republic
Roman Hajek
Faculty of Medicine, University of Ostrava, Czech Republic;Department of Hematooncology, University Hospital Ostrava, Czech Republic
Faith E. Davies
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Gareth J. Morgan
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Brian A. Walker
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Monoclonal gammopathy of undetermined significance is a pre-malignant precursor of multiple myeloma with a 1% risk of progression per year. Although targeted analyses have shown the presence of specific genetic abnormalities such as IGH translocations, RB1 deletion, 1q gain, hyperdiploidy or RAS gene mutations, little is known about the molecular mechanism of malignant transformation. We performed whole exome sequencing together with comparative genomic hybridization plus single nucleotide polymorphism array analysis in 33 flow-cytometry-separated abnormal plasma cell samples from patients with monoclonal gammopathy of undetermined significance to describe somatic gene mutations and chromosome changes at the genome-wide level. Non-synonymous mutations and copy-number alterations were present in 97.0% and in 60.6% of cases, respectively. Importantly, the number of somatic mutations was significantly lower in monoclonal gammopathy of undetermined significance than in myeloma (P